A new model for the pathophysiology of Alzheimer's disease : aluminium toxicity is exacerbated by hydrogen peroxide and attenuated by an amyloid protein fragment and melatonin by Van Rensburg, S. J. et al.
A new model for the
pathophysiology of
Alzheimer's disease
Aluminium toxicity is exacerbated by
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Objectives. Although Alzheimer's disease (AD) is the
leading cause of dementia in developed countries, there is
an as yet unexplained lower prevalence of the disease in
parts of Africa. AD is characterised by a catastrophic loss
of neurons; free radicals (oxidative toxins) have been
implicated in the destruction of the cells through the
process of lipid peroxidative damage of cell membranes.
Previously aluminium (AI) and a fragment of beta amyloid
(Ar3 25 - 35) were shown to exacerbate tree-radical
damage, while melatonin reduced this effect. The aim of
the present study was: (I) to investigate the conditions
detennining the toxicity of AI and A~ 25 - 35; and (;,) to
assess whether melatonin could attenuate the damage
done by both aluminium and the amyloid fragment, thus
suggesting a pathway for the aetiology of AD.
Design. An in vffro model system was used in which free
radicals were generated, causing lipid peroxidation of
platelet membranes, thus simulating the disease process
found in the brain.
Results. 1. AI and Afj 25 - 35 caused lipid peroxidation
in the presence of the iron (11) ion (Fe21, AI being more
toxic than A~ 25 - 35. 2. A~ 25 - 35 attenuated the lipid
peroxidation promoted by AI. 3. Hydrogen peroxide (H,OJ
greatly exacerbated the toxicity of AI and A~ 25 - 35.
4. Melatonin prevented lipid peroxidation by AI and Afj
25 - 35 in the absence of H~O~, but only reduced the
process when H20 2 was present.
Conclusions. In the light of the results obtained from the
present study, the following hypotheses are formulated.
1. In AD, excessive quantities of AI are taken up into the
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brain, where the AI exacerbates iron-induced lipid
peroxidatian in the Iysosomes. 2. In response, the narmaJ
synthetic pathway of amyloid protein is altered to produce
Aa fragments which attenuate the toxicity of AI. In the
process of sequestering the AI and iron, immature plaques
are formed in the brain. 3. Microglia are activated, in an
attempt to destroy the plaques by secreting reactive
oxygen species such as H20 2• At this point in the disease
process, lipid peroxidation causes a catastrophic loss of
brain cells. 4. Melatonin, together with other free radical
scavengers in the brain, reduces the free-radicaJ damage
caused by AI and Aa. except in the latter stages of the
disease process. Since melatonin is produced by the
pineal gland only in the dark, the excess of electric light in
developed countries may help explain why AD is more
prevalent in these countries than in rural Africa.
SAfrMedJ 1997; 87: 1111-1115_
Alzheimer's disease (AD) is characterised by the loss of cells
in certain brain areas, as revealed by temporal lobe-
orientated X-ray computed tomography (CT) scans.' By the
time of clinical AD diagnosis, about 90% of the
hippocampus will have been destroyed. AD is the leading
cause of dementia in developed countries; however, there is
an as yet unexplained lower prevalence of the disease in
parts of Africa,~ even though other dementias such as
vascular dementia and alcohol-related dementia are
common.
An understanding of the action of certain chemically
reactive molecules called free radicals has provided
evidence for their involvement in the destruction of brain
cells.3 Free radicals are toxic byproducts of cellular
biochemical reactions, as found for example when
adenosine triphosphate (ATP) is generated in the
mitochondria.~Free radicals do, however, serve a purpose in
the body, e.g. when cells of the immune system produce
free radicals in order to destroy micro-organisms, or digest
unwanted cell material.s These reactions are usually carefully
controlled for, if left to themselves, free radicals attack living
cells, damaging phospholipids (by causing lipid
peroxidation), proteins and even DNA.~
Chemically speaking, free radicais are ions and molecules
which take part in electron transfer reactions.1 An example is
the iron (11) ion (Fe21, which transfers an electron to
molecular oxygen, thus producing the superoxide radical
(O~-). Superoxide can dismute to form hydrogen peroxide
and, again through the intervention of Fe2+, form hydroxyl
radicals (OHi.'
Superoxide and hydroxyl radicals are extremely damaging
to living cells, especially the cell membranes. Membranes
play an integral part in cell function and health; besides
keeping the cell contents intact, they also determine which
molecules enter and leave cells, and in themselves take part
in chemical reactions. If the damaged membranes cannot be
repaired, the cells die. The principal constituent of
membranes, the phospholipids, are partiCUlarly vulnerable to
free-radical damage (lipid peroxidation) and, as such,
provide a model which can be utilised for studying the
abovementioned reactions in vitro. 3
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In living cells, any free radicals fanned are normally
neutralised by anti-radical defence systems, e.g. free-radical
scavengers (anti-oxidants), enzymes such as glutathione
peroxidase and superoxide dismutase, and iron-binding
proteins such as transferrin.8 However, if these defence
systems are breached, for example, when transferrin does
~ot bind the iron completely, the iron becomes available for
free-radical production. A genetic isoform of transferrin
(Tf C2), which has a decreased iron-binding capacity, is
more frequently present in AD patients than controls and
would therefore abet this process.9 But, in order to combat
increased concentrations of free radicals, other levels of
defence may exist, for example in the form of the hormone,
melatonin, which protects membranes against lipid
peroxidation. 1o
Aluminium (AI)" and beta amyloid (At3)" have both been
shown to exacerbate lipid peroxidation and are implicated in
the aetiology of AD, although the mechanistic pathway has
not been established. In the present study, an in vitro
system was used: (i) to detennine the conditions under
which AI and a fragment of the A~ protein, A~ 25 - 35,
cause lipid peroxidation; and (if) to determine whether
melatonin could attenuate the damage done by either the AI
or the amyloid fragment.
Methods and materials
Chemicals. Diphenylhexatriene (DPH), 2-thiobarbituric acid
(TEA), butylated hydroxytoluene (BHl) and A~ 25 - 35 were
obtained from Sigma Chemical Co; A1,(SOJ"18H,O was
obtained from Merck.
Preparation of membranes. Platelets suspended in
citrate-dextrose buffer, isolated as described previously,!
were obtained from healthy donors. Erythrocytes were
removed by centrifugation at 800 g for 5 minutes. Platelets
were then collected by centrifugation at 3 500 g for 15
minutes. The pellets were resuspended in O.01M phosphate-
buffered saline (PBS), PH 7.4. Cell counts were done on a
Technicon H2 Blood Analyser, which shOWed that there were
no erythrocytes or white blood cells present. Membranes
were prepared by sonication of the suspension with an MSE
sonicator for 10 seconds at an amplitude of 5 microns. The
fragmented membranes were not washed, in order to
maintain their integrity. The protein concentration of the
suspension was 0.07 mg/ml. as determined by the method
of Lowry et al. 13
Determination of lipid peroxidation. Of the membrane
suspension, 100 IJI aJiquots were pipetted into silicon glass
test tubes (Kimble). The follovvng reagents were then added
in sequence, to give final concentrations as indicated:
ascorbate (160 ~M), EDTA (1 0 ~M), A1,(SOJ,.18H,Q (0.1 .
100 ~M), Afl 25 • 35 (0.01 • 100 ~M) or melatonin (1 mM);
FeSO, (40 ~M) and hydrogen peroxide (H,O,; 0.5 - 500 ~M).
The total volume per tube was adjusted to 1 000 ~I with
PBS (pH 5.5, to keep the AI in soluton).
The tubes were incubated at 3rC for 30 minutes. The
follOWing were then added: 1 ml of a 1% (w/v) TBA solution
plus 1 ml of 2.8% (wiv) trichloro-acetic acid. BHT (0.01 %)
was also included to neutralise metaJ-eatalysed auto-
oxidation of Iipids during heating of the mixtures at 1aGoG
for 10 minutes. After cooling, the formation of thiobarbituric
reactive substances (TBARS) was determined by reading the
chromogen at 535 nm in a Beckman DU 640
spectrophotometer. Appropriate corrections to the
absorbance readings were made for the presence of FeS04 -
EDTA and ascorbate in the reaction mixtures. Absorbance
readings at 535 nm are proportional to the TSARS formed,
and are therefore relative values reflecting lipid peroxidation.
Statistical analysis. The statistical significance of the
results was determined by the Mann-Whitney U-test. Results
are the mean ± SEM of 6 observations.
Results
1. AI caused lipid peroxidation onty in the presence of
Fe2+. In Fig. 1 (column A), 100 ~M AI,(SOJ,.18H,O (i.e. 8.1
~M AI) did not use cause lipid peroxidation on its own when
iron was absent, but when 40 IJM iron sulphate and AI were
present simUltaneously (Fig. 1, column 8), a significant
increase in lipid peroxidation (P < 0.05) was observed.
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Fig. 1. Lipid peroxidation recorded in the presence of: A -
100 IJM AI sulphate, without iron, B - 100 IJM AI sulphate plus
40 IJM iron sulphate, C - 100 IJM AI sulphate, 40 IJM iron sulphate
plus 0.5 mM H20 2, D - 100 IJM Al sulphate, 40 IJM iron sulphate,
0.5 mM HlO" plus 1 mM melatonin, E - 100 IJM AI sulphate,
40 IJM iron sulphate, plus 1 mM melatonin. B was significantly
higher than A (P < 0.05)i C was significantly higher than B
(P < 0.005): 0 was significantly lower than C (P < O.oo5)i E was
significantly lower than B (p.< 0.005) (Mann-Whitney U·test).
2, A~ 25 - 35 similarly promoted lipid peroxidation
when iron was present. In. the presence of Fe2+,
0.01 - 1.0 ~M At3 25 . 35 increased the lipid peroxidation
significan~y (P < 0.005) compared wrth At3 25 . 35 at the
same concentrations without iron (Fig. 2).
3. AI was more toxic than the amyloid protein fraction.
In Fig. 3, the relative toxicity of 0.1 - 100 ~M A~ 25·35 and
0.1 - 100 ~M AI,(SOJ,.18H,Q (i.e. 0.008 - 8 ~M AI) was
compared. The AI produced significantly (P < 0.005) more
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lipid peroxidalion than All 25 - 35. The amount of AI used in
the present study (0.216 - 216 ~g/I) was compatible with the
AI concentration recorded previously in the blood of AD
patients (8 - 104 ~g/I)."
LIPID PEROXIDATION (TSARS)
0.09
4. The amyloid protein fraction attenuated AI toxicity.
When AI and All 25 - 35 were present simu~aneously
(Fig. 4), the lipid peroxidation produced was significantly
(P = 0.005) less than with AI on its own. The results from
two separate experiments were combined. However, when
lipid peroxidation was high, as in the presence of H,,02
(Fig. 5), this effect was steadily lost.
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Fig. 2. Upid peroxidation recorded in the presence of increasing
concentrations of A~ 25 - 35, (e) with and (0) without 40 pM iron
sulphate. A13 25 - 35 with iron produced significantly more lipid
peroxidation than A~ 25 - 35 without iron (P < 0.005).
CONCENTRATION (fJ~)
Fig. 4. Lipid peroxidation recorded in the presence 01: (e)
increasing concentrations of AI sulphate; and (0) 100 IJM AI
sulphate plus increasing concentrations of Af3, 25 - 35. A~ 25 - 35
attenuated the toxicity of AI signifieantly (P < 0.005; Mann-
Whitney U-test).
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Fig. 5. Lipid peroxidation in the presence of increasing
concentrations of H20,,:: (0) with 100 IJM AI sulphate; and e-l with
100 pM AI sulphate plus 100 IJM At! 25 - 35.
Fig. 3. Lipid peroxidation recorded in the presence of increasing
concentrations of (e) AI sulphate and (0) AI3 25 - 35. AI sulphate
produced significantly more lipid peroxidation than A13 25 - 35
(P < 0.005).
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5. ~02 greatly exacerbated the toxicity of AI and Aa
25 • 35. Fig. 5 shows that there is a significant increase in
lipid peroxidation with increasing H:z02 concentrations
(P < 0.005). In addition, the attenuating effect of A~ 25 - 35
in the presence of AI is not seen in the presence of H:z02'
although the difference between the effects of AI on its own
and the combination of AI and A~ 25 - 35 was not
significant (Fig. 5). Fig. 1 (column Cl demonstrates
significantly higher lipid peroxidation in the presence of 100
~M AI sulphate, iron sulphate, and 0.5 mM H,O" compared
with iron on its own (Rg. 1, column B).
6. Melatonin eliminated lipid peroxidation caused by
AI and Af3 25 - 35 in the absence of H20 2" In Fig. 1 (column
E) melatonin (1 mM) eliminates lipid peroxidation caused by
AI and A~ 25 - 35, but in the presence of Hp, (0.5 mM;
Rg. 1, column D), the toxicity was only reduced, not
eliminated, even though the concentration of melatonin was
twice that of H20 2•
Discussion
In the current in vitro system, both AI and A~ 25 - 35
exacerbated lipid peroxidation in the presence of iron, AI
being more toxic than A~ 25 - 35. Furthermore, A~ 25 - 35
attenuated the toxicity of AI. H20 2 greatly increased lipid
peroxidation in the presence of both AI and ~ 25 - 35,
except in the absence of iron. Furthermore, melatonin
eliminated lipid peroxidation when H:z02 was absent, and
decreased lipid peroxidation in the presence of H20 2•
The above results, in conjunction with preViously
published data, suggest the following sequence of events in
the aetiology of AD. Firstly, it has previously been
established that there is an increased flow of AI into the
brain in AD. Taylor et al. 1~ demonstrated an increase in blood
AI after an Al citrate drink was ingested by AD patients. In
this group the mean blood Al concentrations increased from
the baseline value of 8.6 ~g11 to 104 ~g11 within 60 minutes,
whereas in age-matched controls, the blood AI level rose
from 7.7 ~g11 to only 37.9 ~g11 over the same time period.
The threshold allowing Al entry into the brain may also be
lower in AD patients, given that Ward and Mason
demonstrated that the concentration of Al in both the
hippocampus and cortex of post-mortem brain samples
from AD patients was 10 times higher than that of non-
demented controls.l~This suggests that the increased
absorption of AI from the gut also results in more AI being
deposited in the brains of these AD patients.
Although AI crosses the blood-brain barrier attached to
molecules such as citrate, the principal carrier is transferrin
(Tf). III In the brain AI is freed from Tt in the lysosom6SS where
the ambient pH is 10w,l1 which keeps AI in solution, i.e. in a
more neurotoxic form. The AI ions then attach themselves to
the headgroups of the phospholipid molecules of cellular
membranes where, on account of their positive charge, they
create artificial openings.' Normally, the headgroups would
foon a barrier against attack by free radicals, protecting the
fatty acid side-chains inside the lipid bilayer, but the 'pores'
allow hydroxyl radicals to reach, attack and damage the
Iipids (lipid peroxidation), thus changing the fluidity of the
membranes.l' It is recognised that abnormalities of the
lysosomal system precede the appearance of tangles and
plaques in the neurons of AD patients.19
The role of amyloid in AD has been a subject of debate.
The functions of the amyloid precursor protein (APP) include
tissue repair in the brain, cell adhesion, and survival and
growth of neurons in vitro. 2O Shigematsu and McGeer found
that APP accumulated in neuronal processes and microglia
following intracerebral administration of Al salts in rat brain.21
It has also been shown that amyloid fragments are
generated in lysosomes.22
The abovementioned lipid peroxidation causes a 4
Angstrom units reduction in the lipid bilayer width,Z3
exposing the transmembrane portion of the APP to
proteolytic secretase enzymes which cleave the APP at a
site which is normally not accessible to these enzymes,24
producing insoluble Af3 fragments. Increased production
(Le. not only an accumulation21) of APP may well occur in
response to increased Al levels in neurons. We hypothesise
that APp, being a 'sticky protein', is meant to bind AI and
sequester it. Owing to the membrane damage and faulty
cleavage of the APp, large amounts of insoluble Af3 are
produced instead, although Af3 also binds to metals such as
AI and iron.?5 Sequestering of these metals by amyloid would
result in a temporary decrease in lipid peroxidation.
Increasing levels of AI result in the formation of immature
amyloid plaques, which 'hold' the AI, because the brain
cannot destroy a metal. At this stage AD progresses slOWly.
The plaques represent foreign material in the brain. We
hypothesise that this activates the microglia (brain
phagocytes), which start to secrete reactive oxygen species
such as H201.~ Microglia, whose presence in the centre of
mature plaques has been demonstrated, are capable of
destroying nervous system tissue for scavenging purposes.26
However, since the plaques consist of insoluble amyloid in
the ~-sheet conformation, they will be resistant to
degradation by the microglia, which continue to produce
more H20 2• As is evident from the results of the present
study, H20 2 greatly exacerbates lipid peroxidation, and in
these circumstances, A~ does not have a protective effect
against AI-initiated lipid peroxidation (Fig. 5). This may be
the cause of the catastrophic phase of cell loss seen in the
brains of AD patients (15.1 % par year, v. 1.5% per year in
heaithy controls)."
Finally, it was demonstrated that melatonin eliminates lipid
peroxidation by AI and A~ 25 - 35, but in the absence of
H:z02. When 0.5 mM ~02 is present, melatonin attenuates
but does not neutralise lipid peroxidation.
Melatonin, a hormone secreted by the pineal gland, is of
interest in diseases associated with ageing, such as AD,
since it is known to decrease in concentration with age.2'
The functions of melatonin include regulation of secretion of
other hormones ~.e. regulation of the body's biological
clock)," and it has recently been implicated as a further level
of defence against lipid peroxidation. 10 Melatonin is secreted
only in the dark. Provided the person is in total darkness,
melatonin lev:els start to rise at 21 hOD, peaking between
02hOO and O4hOO, whereafter they decline. In the presence
of electric light of sufficient intensity at night lime, no
melatonin is produced;2SI hence the availability of melatonin
as free-radical scavenger may be compromised in Western
societies, where the use of electric light is excessive. This
may help explain the finding of a low prevalence of AD in
rural communities in Africa.
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Conclusions
In the light of the above hypothesis, a few suggestions may
be offered as to how we should combat AD.
1. It could be suggested that AI be removed from the
diet. AI in solution has been found to be more toxic than Al
in food,JO and drinking tea ('rooibos' herbal tea excluded) has
been shown to increase AI levelspl However, it may be more
profitable in the end to find the reason why the natural
barriers against AI uptake in the gut and the blood-brain
barrier are lifted in AD. In AD, more than anything else,
prevention will be better than cure.
2. During the phase where AD progresses slowly, it will be
of use to ensure that all protective systems against free-
radical damage are functioning optimally. This would include
taking a wide range of anti-oxidant supplements along with
cognition-enhancing drugs. In addition, the damaged
phospholipids would have to be replaced by
supplementation with essential fatty acids.32
3. In the catastrophic phase, where the brain is in an
inflammatory state, anti-inflammatory drugs may be of use.J3
4. Melatonin, together with other free-radical scavengers
in the brain, reduces free radical damage_ Since melatonin is
produced by the pineal gland only in the dark, we may have
to reconsider the effects late-night living may have qn our
health in old age. In addition, supplementation with
melatonin could be considered.10
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